#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Czech Rheumatology / 2021 - 3

The role of calprotectin in the pathogenesis of rheumatoid arthritis and its use as a biomarker

Download PDF Česká verzia

Authors: N. Petrovská;  M. Filková
Authors place of work: Revmatologická klinika 1. LF UK, Praha ;  Revmatologický ústav Praha
Published in the journal: Čes. Revmatol., 29, 2021, No. 3, p. 144-149.
Category: Review Article

Summary

Rheumatoid arthritis is a chronic inflammatory autoimmune disease typically affecting the synovial membrane, leading to pannus formation due to interaction among stromal and inflammatory cells and angiogenesis. Calprotectin is an S100A8/S100A9 heterodimer produced by activated neutrophils, monocytes, and macrophages in inflammatory tissue and circulation. In patients with RA, it is mainly produced locally in affected joints promoting inflammation, cartilage destruction, and bone resorption. Calprotectin can be detected in the circulation and used as a soluble biomarker. It appears to be a better marker of disease activity than typically used acute phase reactants; moreover, it can be used as a predictive marker of radiographic progression, therapeutic response, and disease flare.

Keywords:

disease activity – Pathogenesis – rheumatoid arthritis – calprotectin – biomarker

Zdroje
  1. Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012; 71(5): 638–641.
  2. Petrovska N, Prajzlerova K, Vencovsky J, Senolt L, Filkova M. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmun Rev 2021; 20(5): 102797.
  3. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2017; 19(1): 110.
  4. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004; 50(12): 3762–3771.
  5. Eue I, Pietz B, Storck J, Klempt M, Sorg C. Transendothelial mi[1]gration of 27E10+ human monocytes. Int Immunol 2000; 12(11): 1593–1604.
  6. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Yamamoto H, et al. The S100A8/A9 heterodimer amplifies proin[1]flammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein ki[1]nase in rheumatoid arthritis. Arthritis Res Ther 2006; 8(3): R69.
  7. van Lent PL, Grevers L, Blom AB, Sloetjes A, Mort JS, Vogl T, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008; 67(12): 1750–1758.
  8. Malemud CJ. Myeloid-related protein activity in rheumatoid arthritis. Int J Inflam 2011; 2011: 580295.
  9. Garcia-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, et al. Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longi[1]tudinal cohort. Mol Diagn Ther 2013; 17(1): 49–56.
  10. Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomar[1]ker for rheumatoid arthritis: a  systematic review. J Rheumatol 2015; 42(5): 760–770.
  11. Mansour HE, Abdullrhman MA, Mobasher SA, El Mallah R, Abaza N, Hamed F, et al. Serum Calprotectin in Rheumatoid Arthritis: A Promising Diagnostic Marker, How Far Is It Related to Activity and Sonographic Findings? J Med Ultrasound 2017; 25(1): 40–46.
  12. Hurnakova J, Hulejova H, Zavada J, Hanova P, Komarc M, Mann H, et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS One 2017; 12(8): e0183420.
  13. Hammer HB, Odegard S, Fagerhol MK, Landewe R, van der Heijde D, Uhlig T, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007; 66(8): 1093–1097.
  14. Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis 2015; 74(3): 499–505.
  15. Asif Amin M, Fox DA, Ruth JH. Synovial cellular and molecu[1]lar markers in rheumatoid arthritis. Semin Immunopathol 2017; 39(4): 385–393.
  16. Korndorfer IP, Brueckner F, Skerra A. The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-heli[1]ces can determine specific association of two EF-hand proteins. J Mol Biol 2007; 370(5): 887–898.
  17. Youssef P, Roth J, Frosch M, Costello P, Fitzgerald O, Sorg C, et al. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membra[1]ne. J Rheumatol 1999; 26(12): 2523–2528.
  18. Baillet A, Trocme C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford) 2010; 49(4): 671–682.
  19. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998; 160(3): 1427–1435.
  20. Carrion M, Juarranz Y, Martinez C, Gonzalez-Alvaro I, Pablos JL, Gutierrez-Canas I, et al. IL-22/IL-22R1 axis and S100A8/A9 alar[1]mins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford) 2013; 52(12): 2177–2186.
  21. Grevers LC, de Vries TJ, Vogl T, Abdollahi-Roodsaz S, Sloetjes AW, Leenen PJ, et al. S100A8 enhances osteoclastic bone resorp[1]tion in vitro through activation of Toll-like receptor 4: implica[1]tions for bone destruction in murine antigen-induced arthritis. Arthritis Rheum 2011; 63(5): 1365–1375.
  22. Drynda S, Ringel B, Kekow M, Kuhne C, Drynda A, Glocker MO, et al. Proteome analysis reveals disease-associated marker pro[1]teins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNF-alpha therapy. Pathol Res Pract 2004; 200(2): 165–171.
  23. Brun JG, Haga HJ, Boe E, Kallay I, Lekven C, Berntzen HB, et al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol 1992; 19(6): 859–862.
  24. Jonsson MK, Sundlisaeter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, et al. Calprotectin as a marker of inflammation in pati[1]ents with early rheumatoid arthritis. Ann Rheum Dis 2017; 76(12): 2031–2037.
  25. Inciarte-Mundo J, Ruiz-Esquide V, Hernandez MV, Canete JD, Cabrera-Villalba SR, Ramirez J, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford) 2015; 54(12): 2239–2243.
  26. Nordal HH, Brokstad KA, Solheim M, Halse AK, Kvien TK, Hammer HB. Calprotectin (S100A8/A9) has the strongest associa[1]tion with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther 2017; 19(1): 3.
  27. Andres Cerezo L, Mann H, Pecha O, Plestilova L, Pavelka K, Vencovsky J, et al. Decreases in serum levels of S100A8/9 (calpro[1]tectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2011; 13(4): R122.
  28. Hurnakova J, Hulejova H, Zavada J, Komarc M, Cerezo LA, Mann H, et al. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clin Rheumatol 2018; 37(8): 2055–2062.
  29. Hammer HB, Odegard S, Syversen SW, Landewe R, van der Heijde D, Uhlig T, et al. Calprotectin (a major S100 leucocyte pro[1]tein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69(1): 150–154.
  30. Hammer HB, Haavardsholm EA, Kvien TK. Calprotectin (a ma[1]jor leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a  longitudinal study of patients with very early rheumatoid arthritis. Scand J Rheumatol 2008; 37(3): 179–182.
  31. Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, et al. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther 2015; 17: 252.
  32. Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble bio[1]marker calprotectin (an S100 protein) is associated to ultraso[1]nographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther 2011; 13(5): R178.
  33. Hurnakova J, Hulejova H, Zavada J, Komarc M, Hanova P, Klein M, et al. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS One 2016; 11(11): e0165498.
  34. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27(1): 261–263.
  35. Zijlstra TR, Bernelot Moens HJ, Bukhari MA. The rheumatoid arthritis articular damage score: first steps in developing a clini[1]cal index of long term damage in RA. Ann Rheum Dis 2002; 61(1): 20–23.
  36. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999; 26(3): 705–711.
  37. Patro PS, Singh A, Misra R, Aggarwal A. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate. J Rheumatol 2016; 43(4): 731– 737.
  38. Inciarte-Mundo J, Ramirez J, Hernandez MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Res Ther 2018; 20(1): 275.
  39. Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019; 56(5): 307–320.
  40. Grossi V, Infantino M, Manfredi M, Meacci F, Bellio E, Bellio V, et al. A  Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis. Curr Rheumatol Rev 2017; 13(2): 93–97.
  41. Ometto F, Friso L, Astorri D, Botsios C, Raffeiner B, Punzi L, et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood) 2017; 242(8): 859–873
Štítky
Dermatology & STDs Paediatric rheumatology Rheumatology
Článek Baricitinib in the treatment of rheumatoid arthritis in routine clinical practice – results from the Czech National ATTRA Registry
Článek Ošetřovatelský manuál pro perioperační péči pacienta se zánětlivými revmatickými nemocemi
Článek Calcium PyroPhosphate Deposition disease
Článok vyšiel v časopise

Czech Rheumatology

Číslo 3
2021 Číslo 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#